메뉴 건너뛰기




Volumn 13, Issue 5, 2014, Pages 525-532

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: A multicenter experience

Author keywords

Boceprevir; Drug drug interaction; Early virological response; Sustained virological response; Telaprevir

Indexed keywords

BOCEPREVIR; CYCLOSPORIN; PEGETRON; PEGINTERFERON ALPHA2A; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TACROLIMUS; TELAPREVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; CARRIER PROTEIN; IMMUNOSUPPRESSIVE AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; VIRUS PROTEIN; VIRUS RNA;

EID: 84906053376     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31252-9     Document Type: Article
Times cited : (24)

References (31)
  • 2
    • 0033998786 scopus 로고    scopus 로고
    • The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States
    • Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
    • (2000) Hepatology , vol.31 , pp. 777-782
    • Armstrong, G.L.1    Alter, M.J.2    McQuillan, G.M.3    Margolis, H.S.4
  • 3
    • 0036828784 scopus 로고    scopus 로고
    • The burden of hepatitis C in the United States
    • Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36: S30-4.
    • (2002) Hepatology , vol.36
    • Kim, W.R.1
  • 4
    • 0036207348 scopus 로고    scopus 로고
    • The association between hepatitis C infection and survival after orthotopic liver transplantation
    • Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
    • (2002) Gastroenterology , vol.122 , pp. 889-896
    • Forman, L.M.1    Lewis, J.D.2    Berlin, J.A.3    Feldman, H.I.4    Lucey, M.R.5
  • 6
    • 18444415726 scopus 로고    scopus 로고
    • Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients
    • Berenguer M, Prieto M, San JF, Rayon JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 02-10.
    • (2002) Hepatology , vol.36 , pp. 2-10
    • Berenguer, M.1    Prieto, M.2    San, J.F.3    Rayon, J.M.4    Martinez, F.5    Carrasco, D.6    Moya, A.7
  • 8
    • 0036793302 scopus 로고    scopus 로고
    • Natural history of recurrent hepatitis C
    • Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14-8.
    • (2002) Liver Transpl , vol.8
    • Berenguer, M.1
  • 9
    • 33847007641 scopus 로고    scopus 로고
    • Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy)
    • Bahra M, Neumann UP, Jacob D, Langrehr JM, Berg T, Neuhaus R, Neuhaus P. Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy). Transplantation 2007; 83: 351-3.
    • (2007) Transplantation , vol.83 , pp. 351-353
    • Bahra, M.1    Neumann, U.P.2    Jacob, D.3    Langrehr, J.M.4    Berg, T.5    Neuhaus, R.6    Neuhaus, P.7
  • 10
    • 46349089961 scopus 로고    scopus 로고
    • Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin
    • Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-87.
    • (2008) J Hepatol , vol.49 , pp. 274-287
    • Berenguer, M.1
  • 11
    • 52149121573 scopus 로고    scopus 로고
    • Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies
    • Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, Leandro G, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
    • (2008) J Viral Hepat , vol.15 , pp. 699-709
    • Xirouchakis, E.1    Triantos, C.2    Manousou, P.3    Sigalas, A.4    Calvaruso, V.5    Corbani, A.6    Leandro, G.7
  • 12
    • 33745343818 scopus 로고    scopus 로고
    • Interferon based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis
    • Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-99.
    • (2006) Am J Transplant , vol.6 , pp. 1586-1599
    • Wang, C.S.1    Ko, H.H.2    Yoshida, E.M.3    Marra, C.A.4    Richardson, K.5
  • 13
    • 33846589289 scopus 로고    scopus 로고
    • Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation
    • Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo CG, Lampasi F, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-65.
    • (2007) J Hepatol , vol.46 , pp. 459-465
    • Picciotto, F.P.1    Tritto, G.2    Lanza, A.G.3    Addario, L.4    De Luca, M.5    Di Costanzo, C.G.6    Lampasi, F.7
  • 14
    • 39649100163 scopus 로고    scopus 로고
    • Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation
    • Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-87.
    • (2008) Am J Transplant , vol.8 , pp. 679-687
    • Berenguer, M.1    Palau, A.2    Aguilera, V.3    Rayon, J.M.4    Juan, F.S.5    Prieto, M.6
  • 15
    • 84879551010 scopus 로고    scopus 로고
    • Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation
    • Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
    • (2013) Liver Transpl , vol.19 , pp. 690-700
    • Pungpapong, S.1    Aqel, B.A.2    Koning, L.3    Murphy, J.L.4    Henry, T.M.5    Ryland, K.L.6    Yataco, M.L.7
  • 16
    • 84890558343 scopus 로고    scopus 로고
    • Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience
    • Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86.
    • (2014) J Hepatol , vol.60 , pp. 78-86
    • Coilly, A.1    Roche, B.2    Dumortier, J.3    Leroy, V.4    Botta-Fridlund, D.5    Radenne, S.6    Pageaux, G.P.7
  • 17
    • 84870862182 scopus 로고    scopus 로고
    • Telaprevir based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data
    • Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP, et al. Telaprevir based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-70.
    • (2012) Liver Transpl , vol.18 , pp. 1464-1470
    • Werner, C.R.1    Egetemeyr, D.P.2    Lauer, U.M.3    Nadalin, S.4    Königsrainer, A.5    Malek, N.P.6    Berg, C.P.7
  • 18
    • 84868208266 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers
    • Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-30.
    • (2012) Hepatology , vol.56 , pp. 1622-1630
    • Hulskotte, E.1    Gupta, S.2    Xuan, F.3    van Zutven, M.4    O'Mara, E.5    Feng, H.P.6    Wagner, J.7
  • 19
    • 0029778988 scopus 로고    scopus 로고
    • An algorithm for the grading of activity in chronic hepatitis C
    • The METAVIR Cooperative Study Group
    • Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
    • (1996) Hepatology , vol.24 , pp. 289-293
    • Bedossa, P.1    Poynard, T.2
  • 20
    • 80053339008 scopus 로고    scopus 로고
    • An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
    • Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011 54: 433-44
    • (2011) Hepatology , Issue.54 , pp. 433-444
    • Ghany, M.G.1    Nelson, D.R.2    Strader, D.B.3    Thomas, D.L.4    Seeff, L.B.5
  • 21
    • 84878746682 scopus 로고    scopus 로고
    • First Successful Treatment of Post-Liver Transplant Hepatitis C Fibrosing Cholestatic Hepatitis with Boceprevir, Peginterferon and Ribavirin in a Pre-Transplant Null Responder
    • Al Nahdi N, Ford JA, Greanya E, Harrigan JA, Tse I, Steinbrecher UP, Erb SR, et al. First Successful Treatment of Post-Liver Transplant Hepatitis C Fibrosing Cholestatic Hepatitis with Boceprevir, Peginterferon and Ribavirin in a Pre-Transplant Null Responder. Ann Hepatol 2013; 12: 156-60.
    • (2013) Ann Hepatol , vol.12 , pp. 156-160
    • Al Nahdi, N.1    Ford, J.A.2    Greanya, E.3    Harrigan, J.A.4    Tse, I.5    Steinbrecher, U.P.6    Erb, S.R.7
  • 23
    • 58249086156 scopus 로고    scopus 로고
    • Hepatitis C virus therapy in liver transplant recipients, response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis
    • Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, et al. Hepatitis C virus therapy in liver transplant recipients, response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008;14: 1766-77.
    • (2008) Liver Transpl , vol.14 , pp. 1766-1777
    • Roche, B.1    Sebagh, M.2    Canfora, M.L.3    Antonini, T.4    Roque-Afonso, A.M.5    Delvart, V.6    Saliba, F.7
  • 24
    • 33846256585 scopus 로고    scopus 로고
    • Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection post transplantation
    • Bizollon T, Pradat P, Mabrut JY, Radenne S, Ducerf C, Baulieux J, Souquet JC, et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection post transplantation. Am J Transplant 2007; 7: 448-53.
    • (2007) Am J Transplant , vol.7 , pp. 448-453
    • Bizollon, T.1    Pradat, P.2    Mabrut, J.Y.3    Radenne, S.4    Ducerf, C.5    Baulieux, J.6    Souquet, J.C.7
  • 25
    • 33745997054 scopus 로고    scopus 로고
    • Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
    • Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, Rayon JM, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006; 12: 1067-76
    • (2006) Liver Transpl , vol.12 , pp. 1067-1076
    • Berenguer, M.1    Palau, A.2    Fernandez, A.3    Benlloch, S.4    Aguilera, V.5    Prieto, M.6    Rayon, J.M.7
  • 26
    • 84892372669 scopus 로고    scopus 로고
    • End of Treatment Response after Protease-Inhibitor (PI)-based Therapy for Hepatitis C Recurrence after Liver Transplantation: A Multicentric European Experience (Abstract #1422)
    • doi:10.1016/S0168-8278(13)61420-8
    • Coilly A, Dumortier J, Botta-Fridlund D, Latournierie M, Leroy V, Pageaux GP, Giostra CE, et al. End of Treatment Response after Protease-Inhibitor (PI)-based Therapy for Hepatitis C Recurrence after Liver Transplantation: A Multicentric European Experience (Abstract #1422). J Hepatol 58: S572. doi:10.1016/S0168-8278(13)61420-8.
    • J Hepatol , vol.58
    • Coilly, A.1    Dumortier, J.2    Botta-Fridlund, D.3    Latournierie, M.4    Leroy, V.5    Pageaux, G.P.6    Giostra, C.E.7
  • 27
    • 84855244456 scopus 로고    scopus 로고
    • Boceprevir and telaprevir for the treatment of chronic hepatitis C, safety management in clinical practice
    • Hezode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C, safety management in clinical practice. Liver Int 2012; 32: 32-8.
    • (2012) Liver Int , vol.32 , pp. 32-38
    • Hezode, C.1
  • 28
    • 84906303033 scopus 로고    scopus 로고
    • A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy
    • May 5. pii: S0168-8278(14)00300-6. doi:10.1016/j.jhep.2014.04. 037. [Epub ahead of print]
    • Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014 May 5. pii: S0168-8278(14)00300-6. doi:10.1016/j.jhep.2014.04. 037. [Epub ahead of print]
    • (2014) J Hepatol
    • Burton, J.R.1    O'Leary, J.G.2    Verna, E.C.3    Saxena, V.4    Dodge, J.L.5    Stravitz, R.T.6    Levitsky, J.7
  • 30
    • 84855263813 scopus 로고    scopus 로고
    • Telaprevir, an oral protease inhibitor for hepatitis C virus infection
    • Kim JJ, Culley CM, Mohammad RA. Telaprevir, an oral protease inhibitor for hepatitis C virus infection. Am J Health Syst Pharm 2012; 69: 19-33.
    • (2012) Am J Health Syst Pharm , vol.69 , pp. 19-33
    • Kim, J.J.1    Culley, C.M.2    Mohammad, R.A.3
  • 31
    • 70349533037 scopus 로고    scopus 로고
    • Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
    • Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 7: 1105-9.
    • (2009) Nat Genet , vol.7 , pp. 1105-1109
    • Tanaka, Y.1    Nishida, N.2    Sugiyama, M.3    Kurosaki, M.4    Matsuura, K.5    Sakamoto, N.6    Nakagawa, M.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.